Hepatotoxicity of metronidazole in Cockayne syndrome: A clinical report.
Cockayne syndrome
Hepatotoxicity
Metronidazole
Spiramycin
Journal
European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
22
02
2021
revised:
29
10
2021
accepted:
07
11
2021
pubmed:
13
11
2021
medline:
11
3
2022
entrez:
12
11
2021
Statut:
ppublish
Résumé
Cockayne syndrome (CS) is a rare autosomal recessive genetic disorder characterized by growth failure and progressive multisystem dysfunction caused by deficient nucleotide excision repair. Whereas metronidazole (MTZ) hepatotoxicity is quite rare in the general population, cases of severe hepatic reaction to MTZ have been reported in CS patients. We report here the case of a 21-year-old CS patient who presented with jaundice following one week of treatment with MTZ combined with spiramycin for dental care. This case is the first one documented with a liver biopsy. Histopathological analysis revealed portal and lobular inflammation with predominance of neutrophils, ballooning degeneration and severe cholestasis without bile duct damage. The outcome was marked by regression of jaundice over 6 weeks. Analysis of this case highlights the probable responsibility of MTZ and adds support to the recommendation to strictly avoid the prescription of this drug in CS patients.
Identifiants
pubmed: 34768013
pii: S1769-7212(21)00254-8
doi: 10.1016/j.ejmg.2021.104388
pii:
doi:
Substances chimiques
Anti-Infective Agents
0
Metronidazole
140QMO216E
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104388Informations de copyright
Copyright © 2021 Elsevier Masson SAS. All rights reserved.